98%
921
2 minutes
20
Antimicrobial resistance (AMR) is a global threat, especially in fungal pathogens. To optimize the use of available antifungals, we need rapid detection and monitoring tools that rely on high-quality AMR mutation data. Here we present FungAMR, a resource based on manual curation of 501 published studies on AMR mutations in clinically and agriculturally relevant fungal pathogens resulting in 35,792 entries covering 208 drugs, 246 genes and 95 fungal species. Each entry includes gene, mutation site and drug susceptibility data, with confidence scores indicating the strength of the supporting evidence. Data analysis revealed convergent mechanisms of resistance, indicating some potentially universal resistance mutations and mutations that lead to cross-resistance within and across antifungal classes. We also developed a computational tool, ChroQueTas, that leverages FungAMR to screen fungal genomes for AMR mutations. FungAMR is available as a web-searchable interface within the Comprehensive Antibiotic Resistance Database (CARD). These evolving resources promise to facilitate research on antifungal resistance.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1038/s41564-025-02084-7 | DOI Listing |
BMC Microbiol
September 2025
Botany and Microbiology Department, Faculty of Science, Helwan University, Cairo, 11421, Egypt.
Background: The emergence of drug-resistant pathogens has stimulated the need for the development of new antimicrobial agents. Epigenetic modulation by suppressing epigenetic inhibitors, such as 5-azacytidine (5-aza), has been shown to activate silent biosynthetic gene clusters within a fungus and causes the production of novel secondary metabolites. This research examined this epigenetic modification strategy in the poorly studied filamentous fungus, Ceratorhiza hydrophila, which may help induce the additional production of bioactive compounds.
View Article and Find Full Text PDFBMJ Open
September 2025
IDIAP Jordi Gol, Barcelona, Catalonia, Spain
Background: Respiratory tract infection tests are increasingly available in primary care and are expected to expand in the future. However, there is limited understanding of clinicians' views on their benefits and how to effectively integrate them into daily clinical practice.
Objectives: The aim of this study was to explore healthcare professionals' views on using respiratory tract infection tests to safely reduce unnecessary antibiotic prescriptions for respiratory tract infections in primary care based on their experience in routine practice.
Clin Exp Dermatol
September 2025
National Skin Centre, 1 Mandalay Road, Singapore, Singapore.
Antimicrobial-resistant Trichophyton infections have emerged as a significant global health concern. We reviewed the literature on their clinical manifestations, resistance mechanisms, and diagnostic and treatment challenges, focusing on Trichophyton indotineae (T. indotineae).
View Article and Find Full Text PDFACS Infect Dis
September 2025
Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, Texas 75390, United States.
Malaria treatments are compromised by drug resistance, creating an urgent need to discover new drugs. We used a phenotypic high-throughput screening (HTS) platform to identify new antimalarials, uncovering three related pyrrole-, indole-, and indoline-based series with a shared α-azacyclic acetamide core. These compounds showed fast-killing activity on asexual blood-stage parasites, were not cytotoxic, and disrupted parasite intracellular pH and Na regulation similarly to cipargamin (KAE609), a clinically advanced inhibitor of the Na pump (ATP4).
View Article and Find Full Text PDFInt J Antimicrob Agents
September 2025
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada; European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Non-Traditional Antibacterial Therapy (ESGNTA); Phage Canada, Maple, Ontario, Canada; Unity Health Toronto,
With antimicrobial resistance as a worldwide public health concern, bacteriophage (phage) therapy (PT) may help treat bacterial infections. However, given its particularities compared with traditional small molecule drugs, there are variations in how it is regulated worldwide. Regulators are key players governing PT, yet their perspectives have been largely unexplored.
View Article and Find Full Text PDF